Keeping it LITE

Keeping it LITE is an online study about the life experiences and health of LGBTQ+ people living in or near Chicago, Illinois.

Read what the news is saying about us...

To participate, you must be:

  • Near Chicago
  • Be 13-34 years old
  • Identify as LGBTQ+

ATN & iTech

The Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) research program aims to defeat the rising HIV epidemic among adolescents and young adults in the United States. ATN is led by investigators with innovative thinking and novel approaches to increase awareness of HIV status in youth and, for those diagnosed with HIV, increase access to health care.

The UNC/Emory Center for Innovative Technology (iTech) aims to lower the burden of HIV infection by developing and evaluating innovative, interdisciplinary research on technology-based interventions across the HIV prevention and care continuum for at-risk or infected youth aged 15-24 years in the United States.

iTech Studies at the CORE Center

YouThrive is a study that is exploring an online safe space for young people living with HIV to share information, empower and support each other to make healthy choices.

Lynx is a study that is exploring a highly interactive mobile app for young Gay, Bi, Queer and other men to understand possible risks related to sex and increase HIV/STI testing and treatment. Another study called Compare, will compare Lynx to a similar study called MyChoices.

P3 is a study that is exploring a mobile app that uses game and social networking features to encourage and support young LGBTQ+ PrEP users.

LifeSteps is a study that is exploring a counseling to encourage and support young Gay, Bi, Queer and other male PrEP users.

ATEAM

This study is looking at new ways to support PrEP users track their habits to stay fit and stay informed.

HPTN 083

THE HPTN

HPTN 083 is a study that is part of the NIH-DAIDS-funded HIV Prevention Trials Network (HPTN).

HPTN 083

HPTN 083 is a research study that compares the effectiveness of injections and oral tablets as pre-exposure prophylaxis (PrEP) to prevent HIV.